文献速递前列腺癌

前列腺癌盆腔放疗后放射性瘘的系统综述与Meta分析

Radiation-induced Fistulas in Patients With Prior Pelvic Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Urology · 2023-03-23

该系统综述与Meta分析检索PubMed、Embase和Web of Science,最终纳入6项队列研究共7665例1967年至2013年间接受盆腔放疗的患者,中位随访35.5个月。汇总放射性瘘发生率为0.2%(95%CI:0.1-0.4,I²=0.000%,P<.608)。作者认为前列腺癌盆腔放疗患者短期发生瘘的风险似乎较低,但已发表文献有限。

要点

  • 6项队列研究共7665例盆腔放疗患者,放射性瘘汇总发生率为0.2%(95%CI:0.1-0.4)。
  • 再放疗者瘘发生率为0.3%(95%CI:0.1-0.4,P=.762),同步化疗者为0.4%(95%CI:-0.3-1.2,P=.664)。
  • 作者认为前列腺癌盆腔放疗患者短期发生瘘的风险似乎较低。

核心结论

  • 已发表文献中报告前列腺癌放疗后瘘这一不良事件的文献有限,尤其是中长期随访期。
  • 接受盆腔放疗的前列腺癌患者短期发生瘘的风险似乎较低。
  • 随机对照试验的不良事件报告应更加细化,瘘应具体报告,而不是归入泌尿生殖系统或胃肠道不良事件的宽泛类别。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Web of Science(检索日期2020年10月7日)。
  • 最终Meta分析纳入6项队列研究,共7665例1967年至2013年间接受盆腔放疗的患者。
  • 中位随访时间35.5个月(IQR 33.5-57.5)。
  • 采用随机效应模型,用I²统计量量化异质性,用纽卡斯尔-渥太华量表评估偏倚风险。

主要发现

  • 6项队列研究汇总的放射性瘘发生率为0.2%(95%CI:0.1-0.4,I²=0.000%,P<.608)。
  • 再放疗患者瘘发生率为0.3%(95%CI:0.1-0.4,P=.762),与仅接受首程放疗者相比未检测到显著异质性。
  • 同步化疗患者瘘发生率为0.4%(95%CI:-0.3-1.2,P=.664),与仅接受首程放疗者相比未检测到显著异质性。
  • 无随机对照试验符合纳入标准,原因是瘘发生情况的报告语言含糊且不一致。

局限性

  • 已发表文献中报告瘘作为前列腺癌放疗不良事件的文献有限,尤其是中长期随访期。
  • 无随机对照试验符合纳入标准,原因是瘘发生情况的报告语言含糊且不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically aggregate and summarize existing data on fistula prevalence among patients with a history of pelvic radiotherapy for prostate cancer. MATERIALS AND METHODS: We queried PubMed, Embase, and Web of Science on October 7, 2020 for peer-reviewed publications pertaining to radiation-induced fistulas in the pelvis. For meta-analysis, we used the random-effects model. We used the I2 statistic to quantify heterogeneity and the Newcastle-Ottawa Scale to assess risk of bias. RESULTS: Our final meta-analysis included 6 cohort studies with a total of 7665 patients exposed to pelvic radiotherapy between 1967 and 2013. Median follow-up time was 35.5 months (IQR 33.5-57.5). Pooled prevalence of radiation-induced fistula across all 6 cohort studies was 0.2% (95% CI: 0.1-0.4, I2 = 0.000%, P < .608). In subgroup analysis, we did not detect significant heterogeneity in fistula prevalence in patients who were re-irradiated (0.3%, 95% CI: 0.1-0.4; P = .762) or patients on concurrent chemotherapy (0.4%, 95% CI: -0.3 -1.2; P = .664) compared to those receiving their first course of radiotherapy alone. No randomized controlled trials met inclusion criteria due to ambiguous and inconsistent reporting language for fistula occurrence. CONCLUSION: There is limited published literature reporting fistula as an adverse event of prostate cancer radiotherapy, especially in the medium and long-term period. Patients undergoing pelvic radiotherapy for prostate cancer appear at low short-term risk for developing fistulas. Adverse event reporting in randomized controlled trials merits greater granularity where fistulas should be reported with specificity rather than aggregating into broad categories of genitourinary or gastrointestinal adverse events.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sadighian M, Hakam N, Amend G, et al. Radiation-induced Fistulas in Patients With Prior Pelvic Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. Urology. 2023. PMID: 36963666. doi:10.1016/j.urology.2023.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。